This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cabometyx / Cometriq
Drug Names(s): BMS-907351, XL184, cabozantinib, cabozantinib-s-malate, Cometriq (Thyroid), Cabometyx (Renal)
Cabozantinib inhibits the hepatocyte growth factor receptor MET, RET, and the vascular endothelial growth factor receptor 2 VEGFR2, which are key drivers of tumor growth, metastasis, survival, and angiogenesis. Cabozantinib has also exhibited inhibition of other RTKs that have been implicated in various forms of cancer including mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (Flt3) and the endothelial cell RTK receptor (Tie-2). In preclinical efficacy studies, cabozantinib has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breastcancer, lung cancer and glioma.
Cabozantinib is now approved as two different formulations (capsules and tablets) with separate brand names (Cometriq and Cabometyx). Because of the new formulation, the FDA considered the New Drug Application (NDA) in renal cell carcinoma as a separate NDA filing from the initial NDA filing in thyroid cancer. As such, we have added both brand names to this drug profile. All cabozantinib development will be followed under this one drug profile in BioMedTracker.
Revenue splits for this drug are BioMedTracker estimates.
GlaxoSmithKline and Exelixis
GlaxoSmithKline and Exelixis have a partnership focused on the collaboration in 12 programs (XL784, XL647, XL999, XL880, XL184, XL820, XL844, XL281, XL418, XL228 and two earlier stage oncology programs). GlaxoSmithKline has the right to select from these programs up to two compounds at proof-of-concept (completion of Phase IIa clinical trial) or three compounds if GlaxoSmithKline extends the collaboration.
In June 2008, Exelixis announced that the company and GlaxoSmithKline will bring their collaboration to a conclusion on October 27, 2008.
In October 2008, Exelixis announced that GlaxoSmithKline decided not to exercise its option to license XL184, XL281, XL228, XL820, and XL844.
In April 2014, GlaxoSmithKline sent notice to Exelixis of its intent to terminate the development of foretinib and return rights pursuant to the terms and conditions of the...See full deal structure in Biomedtracker
Partners: Swedish Orphan Biovitrum GlaxoSmithKline plc Ipsen SA
Additional information available to subscribers only: